Skip to main content
SpringerLink
Log in

Estimation of the Effect of OAT2-Mediated Active Uptake on Meloxicam Exposure in the Human Liver

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Active uptake mediated by organic anion transporter 2 (OAT2) has been previously hypothesized as a key player in hepatic disposition of its substrates. Previous studies have shown that another hepatic uptake transporter, organic anion transporting polypeptides (OATP) 1B1, significantly elevates liver concentrations of drugs transported by it. As tissue concentration typically governs pharmacodynamics, drug-drug interactions, and toxicity in the liver, it is important to understand if OAT2 functions similarly to OATP1B1 in raising liver exposure. Since this is a research problem that cannot be easily assessed in clinical studies at this time, here we estimated human liver exposure of an OAT2 substrate meloxicam using a deduction method based on physiologically based pharmacokinetic (PBPK) modeling of clinical systemic exposure data. Although in vitro data suggest that OAT2-mediated active uptake is involved in meloxicam disposition, the modeling result concludes that its unbound liver exposure is unlikely significantly different from its unbound systemic exposure. This conclusion is further supported by data and modeling from a terminal monkey study and in vitro hepatocyte studies with bovine serum albumin. Overall, based on currently available data, we do not expect that OAT2 has a strong impact on the liver exposure of meloxicam.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Vaidyanathan J, Yoshida K, Arya V, Zhang L. Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1. J Clin Pharmacol. 2016;56(Suppl 7):S59–72.

    Article  CAS  Google Scholar 

  2. Riccardi K, Lin J, Li Z, Niosi M, Ryu S, Hua W, et al. Novel method to predict in vivo liver-to-plasma Kpuu for OATP substrates using suspension hepatocytes. Drug Metab Dispos. 2017;45(5):576–80.

    Article  CAS  Google Scholar 

  3. Li R, Kimoto E, Niosi M, Tess DA, Lin J, Tremaine LM, et al. A study on pharmacokinetics of Bosentan with systems modeling, part 2: prospectively predicting systemic and liver exposure in healthy subjects. Drug Metab Dispos. 2018;46(4):357–66.

    Article  CAS  Google Scholar 

  4. Morse BL, MacGuire JG, Marino AM, Zhao Y, Fox M, Zhang Y, et al. Physiologically based pharmacokinetic modeling of transporter-mediated hepatic clearance and liver partitioning of OATP and OCT substrates in cynomolgus monkeys. AAPS J. 2017;19(6):1878–89.

    Article  CAS  Google Scholar 

  5. Li R, Niosi M, Johnson N, Tess DA, Kimoto E, Lin J, et al. A study on pharmacokinetics of Bosentan with systems modeling, part 1: translating systemic plasma concentration to liver exposure in healthy subjects. Drug Metab Dispos. 2018;46(4):346–56.

    Article  CAS  Google Scholar 

  6. Billington S, Shoner S, Lee S, Clark-Snustad K, Pennington M, Lewis D, et al. Positron emission tomography imaging of [(11) C]rosuvastatin hepatic concentrations and hepatobiliary transport in humans in the absence and presence of cyclosporin a. Clin Pharmacol Ther. 2019.

  7. Kaneko K, Tanaka M, Ishii A, Katayama Y, Nakaoka T, Irie S, et al. A clinical quantitative evaluation of hepatobiliary transport of [(11)C]dehydropravastatin in humans using positron emission tomography. Drug Metab Dispos. 2018;46(5):719–28.

    Article  CAS  Google Scholar 

  8. Bi YA, Lin J, Mathialagan S, Tylaska L, Callegari E, Rodrigues AD, et al. Role of hepatic organic anion transporter 2 in the pharmacokinetics of R- and S-warfarin: in vitro studies and mechanistic evaluation. Mol Pharm. 2018;15(3):1284–95.

    Article  CAS  Google Scholar 

  9. Kimoto E, Mathialagan S, Tylaska L, Niosi M, Lin J, Carlo AA, et al. Organic anion transporter 2-mediated hepatic uptake contributes to the clearance of high-permeability-low-molecular-weight acid and zwitterion drugs: evaluation using 25 drugs. J Pharmacol Exp Ther. 2018;367(2):322–34.

    Article  CAS  Google Scholar 

  10. Li R, Ghosh A, Maurer TS, Kimoto E, Barton HA. Physiologically based pharmacokinetic prediction of telmisartan in human. Drug Metab Dispos. 2014;42(10):1646–55.

    Article  CAS  Google Scholar 

  11. Bi YA, Costales C, Mathialagan S, West M, Eatemadpour S, Lazzaro S, et al. Quantitative contribution of six major transporters to the hepatic uptake of drugs: "SLC-phenotyping" using primary human hepatocytes. J Pharmacol Exp Ther. 2019;370(1):72–83.

    Article  CAS  Google Scholar 

  12. Li R, Bi YA, Vildhede A, Scialis RJ, Mathialagan S, Yang X, et al. Transporter-mediated disposition, clinical pharmacokinetics and cholestatic potential of glyburide and its primary active metabolites. Drug Metab Dispos. 2017;45(7):737–47.

    Article  CAS  Google Scholar 

  13. Bi YA, Mathialagan S, Tylaska L, Fu M, Keefer J, Vildhede A, et al. Organic anion transporter 2 mediates hepatic uptake of tolbutamide, a CYP2C9 probe drug. J Pharmacol Exp Ther. 2018;364(3):390–8.

    Article  CAS  Google Scholar 

  14. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos. 1995;23(11):1206–13.

    CAS  PubMed  Google Scholar 

  15. Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur J Clin Pharmacol. 1995;48(3–4):269–72.

    CAS  PubMed  Google Scholar 

  16. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998;28(1):1–13.

    Article  CAS  Google Scholar 

  17. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006;34(5):880–6.

    Article  CAS  Google Scholar 

  18. Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen KJ, Korhonen T, Neuvonen PJ, et al. Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. Antimicrob Agents Chemother. 2009;53(2):587–92.

    Article  CAS  Google Scholar 

  19. Haario H, Laine M, Mira A, Saksman E. DRAM: efficient adaptive MCMC. Stat Comput. 2006;16(4):339–54.

    Article  Google Scholar 

  20. Riccardi KA, Tess DA, Lin J, Patel R, Ryu S, Atkinson K, et al. A novel unified approach to predict human hepatic clearance for both enzyme- and transporter-mediated mechanisms using suspended human hepatocytes. Drug Metab Dispos. 2019;47(5):484–92.

    Article  CAS  Google Scholar 

  21. Iwasaki S, Kosugi Y, Zhu AZX, Nakagawa S, Sano N, Funami M, et al. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach. Xenobiotica. 2019:Ahead of Print.

  22. Li R, Maurer TS, Sweeney K, Barton HA. Does the systemic plasma profile inform the liver profile? Analysis using a physiologically based pharmacokinetic model and individual compounds. AAPS J. 2016;18(3):746–56.

    Article  CAS  Google Scholar 

  23. Di L, Atkinson K, Orozco CC, Funk C, Zhang H, McDonald TS, et al. In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method. Drug Metab Dispos. 2013;41(12):2018–23.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Translational Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, MA, USA

    Rui Li

  2. Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer Worldwide R&D, Groton, CT, USA

    Sumathy Mathialagan, Jonathan J. Novak, Heather Eng & Keith Riccardi

  3. Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer Worldwide R&D, Cambridge, MA, USA

    John Litchfield

Authors
  1. Rui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumathy Mathialagan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan J. Novak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heather Eng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keith Riccardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John Litchfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rui Li.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 63 kb)

ESM 2

(ZIP 19.9 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, R., Mathialagan, S., Novak, J.J. et al. Estimation of the Effect of OAT2-Mediated Active Uptake on Meloxicam Exposure in the Human Liver. AAPS J 22, 20 (2020). https://doi.org/10.1208/s12248-019-0409-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-019-0409-8

Keywords

Search

Navigation